AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

11 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

23 Aug 2023 07:00:42 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

07 Aug 2023 15:01:06 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

02 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film

27 Jul 2023 06:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET

25 Jul 2023 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit

06 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

29 Jun 2023 07:42:55 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

02 May 2023 15:31:30 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

26 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)

20 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET

18 Apr 2023 07:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets

29 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

07 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET

22 Feb 2023 07:00:56 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

21 Feb 2023 07:00:03 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

06 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

22 Dec 2022 07:00:00 By Nasdaq GlobeNewswire